arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Computer Science · Artificial Intelligence

Stem Cell Engineering and Therapeutic Applications: Emerging Tools for Regenerative Medicine and Disease Modelling

Daksha Tigga

· Zenodo (CERN European Organization for Nuclear Research)

See on the map

Abstract

Abstract: Stem cell engineering has emerged as a transformative field at the intersection of biotechnology and regenerative medicine, offering unprecedented opportunities for both therapeutic intervention and disease modelling. Advances in genetic engineering, biomaterials and tissue culture technologies have significantly enhanced the capacity to manipulate stem cells with precision, enabling their differentiation into specialized lineages for targeted applications (Li et al., 2021). Induced pluripotent stem cells (iPSCs) in particular have provided a patient-specific and ethically acceptable platform for regenerative medicine, facilitating the repair of damaged tissues while reducing risks of immune rejection (Takahashi & Yamanaka, 2006). Recent breakthroughs in CRISPR/Cas9-mediated genome editing have accelerated the ability to model genetic diseases in vitro, offering insights into disease mechanisms and enabling high-throughput drug screening (Hendriks et al., 2020). Engineered stem cell–derived organoids further provide physiologically relevant systems to mimic human organs, bridging the gap between traditional cell culture and in vivo studies (Yin et al., 2016). Parallel innovations in biomaterials and 3D bioprinting have improved stem cell delivery and survival, increasing the clinical success rates of transplantation therapies (Murphy & Atala, 2014). Despite these advances, challenges such as tumorigenicity, ethical concerns, and limited long-term graft integration remain barriers to clinical translation (Trounson & McDonald, 2015). Addressing these issues requires interdisciplinary strategies, including safer reprogramming methods, immunomodulation and scalable biomanufacturing approaches. In conclusion, stem cell engineering holds immense promise for regenerative medicine and disease modelling. With continued innovation, integration of nanotechnology, synthetic biology and personalized medicine, stem cell–based therapies are poised to redefine the future of healthcare by moving from experimental research toward mainstream clinical applications. Keywords: Stem cell engineering; regenerative medicine; induced pluripotent stem cells; CRISPR/Cas9; organoids; 3D bioprinting References: 1. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676. 2. Murphy, S. V., & Atala, A. (2014). 3D bioprinting of tissues and organs. Nature Biotechnology, 32(8), 773–785. 3. Yin, X., Mead, B. E., Safaee, H., Langer, R., Karp, J. M., & Levy, O. (2016). Engineering stem cell organoids. Cell Stem Cell, 18(1), 25–38. 4. Hendriks, D., Clevers, H., & Artegiani, B. (2020). CRISPR–Cas tools and their applications in genetic engineering of human stem cells and organoids. Cell Stem Cell, 27(5), 705–731. 5. Li, M., Izpisua Belmonte, J. C. (2021). Organoids—preclinical models of human disease. New England Journal of Medicine, 385, 490–498. 6. Trounson, A., & McDonald, C. (2015). Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell, 17(1), 11–22.

More like this